The two most recently approved classes of therapeutic agents for the treatment of type 2 diabetes, glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors exert their actions through potentiation of incretin receptor signaling. This review examines their mechanisms of action, benefits and adverse effects.